Loading...
Loading...
MNOV| Name | Value |
|---|---|
| Revenues | 1,000.0M |
| Cost of Revenue | 0.0M |
| Gross Profit | 1,000.0M |
| Operating Expense | 2,146.9M |
| Operating I/L | -1,146.9M |
| Other Income/Expense | 0.4M |
| Interest Income | 437.9M |
| Pretax | -0.7M |
| Income Tax Expense | -1,146.2M |
| Net Income/Loss | -0.7M |
MediciNova, Inc. is a biopharmaceutical company specializing in the development of novel small molecule therapeutics for serious diseases with unmet medical needs. The company's primary focus is on the development of MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for the treatment of various neurological disorders, including multiple sclerosis, amyotrophic lateral sclerosis, and substance dependence and addiction. Additionally, the company's product pipeline includes MN-221 (bedoradrine) for acute exacerbations of asthma, MN-001 (tipelukast) for fibrotic diseases, and MN-029 (denibulin) for solid tumor cancers.
